Enliven Therapeutics CFO Benjamin Hohl sells 130,688 in stock
ELVN Stock | 23.79 0.63 2.58% |
About 68% of Enliven Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Enliven Therapeutics stock suggests that many investors are alarmed at this time. Enliven Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Enliven Therapeutics. Many technical investors use Enliven Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Enliven |
Enliven Therapeutics CFO Benjamin Hohl sells 130,688 in stock
Read at investing.com
Enliven Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Enliven Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Enliven Therapeutics Fundamental Analysis
We analyze Enliven Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enliven Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enliven Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Enliven Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Enliven Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Enliven Therapeutics stock to make a market-neutral strategy. Peer analysis of Enliven Therapeutics could also be used in its relative valuation, which is a method of valuing Enliven Therapeutics by comparing valuation metrics with similar companies.
Peers
Enliven Therapeutics Related Equities
CMPX | Compass Therapeutics | 7.88 | ||||
NVCT | Nuvectis Pharma | 2.91 | ||||
MLTX | MoonLake Immunotherapeuti | 2.09 | ||||
REPL | Replimune | 1.58 | ||||
IMRX | Immuneering Corp | 1.40 | ||||
PMVP | Pmv Pharmaceuticals | 0.63 | ||||
LYRA | Lyra Therapeutics | 0.48 | ||||
INBX | Inhibrx | 0.27 | ||||
GPCR | Structure Therapeutics | 0.06 | ||||
CELC | Celcuity LLC | 0.70 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
GOSS | Gossamer Bio | 1.26 | ||||
KRON | Kronos Bio | 1.87 | ||||
ELYM | Eliem Therapeutics | 1.90 | ||||
AVTE | Aerovate Therapeutics | 2.23 |
Check out Enliven Therapeutics Hype Analysis, Enliven Therapeutics Correlation and Enliven Therapeutics Performance. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.